Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;38(2):93-98.
doi: 10.1017/ipm.2020.94. Epub 2020 Aug 19.

Psychedelic science in post-COVID-19 psychiatry

J R Kelly  1   2 , M T Crockett  3 , L Alexander  4 , M Haran  5 , A Baker  6 , L Burke  6 , C Brennan  6 , V O'Keane  1   2
Affiliations

Psychedelic science in post-COVID-19 psychiatry

J R Kelly et al. Ir J Psychol Med. 2021 Jun.

Abstract

The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. The COMPASS Pathways (COMPASS) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (TRD) is underway to determine the safety, efficacy and optimal dose of psilocybin. Results from the Imperial College London Psilodep-RCT comparing the efficacy and mechanisms of action of psilocybin therapy to the selective serotonin reuptake inhibitor (SSRI) escitalopram will soon be published. However, the efficacy and safety of psilocybin therapy in conjunction with SSRIs in TRD is not yet known. An additional COMPASS study, with a centre in Dublin, will begin to address this question, with potential implications for the future delivery of psilocybin therapy. While at a relatively early stage of clinical development, and notwithstanding the immense challenges of COVID-19, psilocybin therapy has the potential to play an important therapeutic role for various psychiatric disorders in post-COVID-19 clinical psychiatry.

Keywords: COVID-19; Coronavirus; depression; psilocybin; psychedelics; selective serotonin reuptake inhibitors; treatment-resistant depression.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflicts of interest to disclose.

References

    1. Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR (2020. a). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports 10, 2214. - PMC - PubMed
    1. Barrett FS, Krimmel SR, Griffiths R, Seminowicz DA, Mathur BN (2020. b). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage, 116980. - PMC - PubMed
    1. Bonson KR, Buckholtz JW, Murphy DL (1996). Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14, 425–436. - PubMed
    1. Bonson KR, Murphy DL (1996). Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 73, 229–233. - PubMed
    1. Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sanches R, Crippa JAS, Hallak JEC, de Araujo DB, Riba J (2015). Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. European Neuropsychopharmacology 25, 483–492. - PubMed

Publication types